Compounds > sericoside

Page last updated: 2024-11-12

sericoside

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

sericoside: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID Source	ID
PubMed CID	76972524
MeSH ID	M0457723

Synonyms (16)

Synonym
einecs 259-586-3
sericoside
beta-d-glucopyranosyl (2alpha,3beta,4beta,19alpha)-2,3,19,23-tetrahydroxyolean-12-en-28-oate
4-epi-sericoside
s4a9325kv4 ,
unii-s4a9325kv4
sericoside [inci]
olean-12-en-28-oic acid, 2,3,19,23-tetrahydroxy-, .beta.-d-glucopyranosyl ester, (2.alpha.,3.beta.,4.beta.,19.alpha.)-
sericoside vinyals
olean-12-en-28-oic acid, 2,3,19,23-tetrahydroxy, glucopyranosyl ester
DTXSID001019848
Q27288574
[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] (1s,4ar,6ar,6as,6br,8ar,9s,10r,11r,12ar,14bs)-1,10,11-trihydroxy-9-(hydroxymethyl)-2,2,6a,6b,9,12a-hexamethyl-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylate
CS-0568243
HY-N10496
AKOS040734747

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	4 (80.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (20.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	5 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
lactic acid Lactic Acid: A normal intermediate in the fermentation (oxidation, metabolism) of sugar. The concentrated form is used internally to prevent gastrointestinal fermentation. (From Stedman, 26th ed). 2-hydroxypropanoic acid : A 2-hydroxy monocarboxylic acid that is propanoic acid in which one of the alpha-hydrogens is replaced by a hydroxy group.	2.02	1	0	2-hydroxy monocarboxylic acid	algal metabolite; Daphnia magna metabolite
glycerol Moon: The natural satellite of the planet Earth. It includes the lunar cycles or phases, the lunar month, lunar landscapes, geography, and soil.	2.03	1	0	alditol; triol	algal metabolite; detergent; Escherichia coli metabolite; geroprotector; human metabolite; mouse metabolite; osmolyte; Saccharomyces cerevisiae metabolite; solvent
oleanolic acid [no description available]	2.94	4	0	hydroxy monocarboxylic acid; pentacyclic triterpenoid	plant metabolite
glucose, (beta-d)-isomer beta-D-glucose : D-Glucopyranose with beta configuration at the anomeric centre.. (1->4)-beta-D-glucan : A beta-D-glucan in which the glucose units are connected by (1->4) linkages.. (1->3)-beta-D-glucan : A beta-D-glucan in which the glucose units are connected by (1->3) linkages.	2.94	4	0	D-glucopyranose	epitope; mouse metabolite
sulfur Sulfur: An element that is a member of the chalcogen family. It has an atomic symbol S, atomic number 16, and atomic weight [32.059; 32.076]. It is found in the amino acids cysteine and methionine.	2.01	1	0	chalcogen; nonmetal atom	macronutrient
beta-escin [no description available]	2.04	1	0
trithiacyclononane trithiacyclononane: a ligand for potential technetium and rhenium radiopharmaceuticals	2.01	1	0
arjunetin arjunetin: RN given for (2alpha,3beta,19alpha)-isomer; has antifeedant, growth inhibitory, and oviposition-deterrent activities against Spilartia obliqua; structure in first source	2.04	1	0

Condition	Indicated	Relationship Strength	Studies	Trials
Aging The gradual irreversible changes in structure and function of an organism that occur as a result of the passage of time.	0	7.6	1	0
Acute Liver Injury, Drug-Induced [description not available]	0	2.02	1	0
Black Fever [description not available]	0	2.02	1	0
Kidney Diseases Pathological processes of the KIDNEY or its component tissues.	0	2.02	1	0
Leishmaniasis, Visceral A chronic disease caused by LEISHMANIA DONOVANI and transmitted by the bite of several sandflies of the genera Phlebotomus and Lutzomyia. It is commonly characterized by fever, chills, vomiting, anemia, hepatosplenomegaly, leukopenia, hypergammaglobulinemia, emaciation, and an earth-gray color of the skin. The disease is classified into three main types according to geographic distribution: Indian, Mediterranean (or infantile), and African.	0	2.02	1	0
Chemical and Drug Induced Liver Injury A spectrum of clinical liver diseases ranging from mild biochemical abnormalities to ACUTE LIVER FAILURE, caused by drugs, drug metabolites, herbal and dietary supplements and chemicals from the environment.	0	2.02	1	0
Obesity A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).	0	2.03	1	0